Hematology and Oncology Book

http://www.fpnotebook.com/

Hydroxyurea

Advertisement

  1. Mechanism
    1. Increases production of fetal Hemoglobin (HbF)
  2. Indications
    1. Indicated for 3 or more crises per year, over age 18
  3. Monitoring
    1. Baseline
      1. Complete Blood Count
      2. Reticulocyte Count
      3. Hemoglobin F
      4. Renal Function tests
      5. Liver Function Tests
      6. Pregnancy Test
    2. Follow-up labs (periodically and with dose change)
      1. Complete Blood Count
      2. Renal Function tests
      3. Liver Function Tests
      4. Hemoglobin F
  4. Efficacy
    1. Reduces Sickle Cell Crisis by 50%
    2. Reduces Sickle Cell Anemia mortality
      1. Steinberg (2003) JAMA 289:1645

hydroxyurea (C0020402)

Definition (MSH)An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Definition (CSP)ribonucleotide reductase inhibitor which thereby lowers intracellular dNTP pools and slows DNA replication and repair; used as antineoplastic, cell devision inhibitor, and possible chemotherapy for sickle cell anemia.
Definition (NCI)An anticancer drug that belongs to the family of drugs called antimetabolites.
Definition (PDQ)A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle. This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40685&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=40685&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C560" NCI Thesaurus)
Definition (NCI)A monohydroxyl-substituted urea (hydroxycarbamate) antimetabolite. Hydroxyurea selectively inhibits ribonucleoside diphosphate reductase, an enzyme required to convert ribonucleoside diphosphates into deoxyribonucleoside diphosphates, thereby preventing cells from leaving the G1/S phase of the cell cycle. This agent also exhibits radiosensitizing activity by maintaining cells in the radiation-sensitive G1 phase and interfering with DNA repair. (NCI04)
ConceptsOrganic Chemical (T109) , Pharmacologic Substance (T121)
EnglishHU, HYD, Hydroxycarbamid, Hydroxycarbamide, hydroxyurea, HYDROXYUREA PREPARATION
Spanishhidroxiurea
CreditsDerived from the NIH UMLS (Unified Medical Language System)



Navigation Tree